vs
Side-by-side financial comparison of IDEX Corporation (IEX) and Pediatrix Medical Group, Inc. (MD). Click either name above to swap in a different company.
Pediatrix Medical Group, Inc. is the larger business by last-quarter revenue ($493.8M vs $398.4M, roughly 1.2× IDEX Corporation). IDEX Corporation runs the higher net margin — 30.1% vs 6.8%, a 23.3% gap on every dollar of revenue. On growth, IDEX Corporation posted the faster year-over-year revenue change (16.7% vs -1.7%). Over the past eight quarters, Pediatrix Medical Group, Inc.'s revenue compounded faster (-0.1% CAGR vs -29.4%).
IDEX can refer to several things, including:International Defence Exhibition, a biennial arms and defense technology sales exhibition IDEX Corporation, a publicly listed company that makes fluidics systems and specialty engineered products Ideanomics, a publicly traded company that trades under the IDEX ticker symbol.
Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.
IEX vs MD — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $398.4M | $493.8M |
| Net Profit | $120.0M | $33.7M |
| Gross Margin | 99.9% | — |
| Operating Margin | 43.3% | 9.9% |
| Net Margin | 30.1% | 6.8% |
| Revenue YoY | 16.7% | -1.7% |
| Net Profit YoY | 25.7% | 10.5% |
| EPS (diluted) | $1.61 | $0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | $398.4M | — | ||
| Q1 26 | $407.7M | — | ||
| Q4 25 | $899.1M | $493.8M | ||
| Q3 25 | $878.7M | $492.9M | ||
| Q2 25 | $865.4M | $468.8M | ||
| Q1 25 | $814.3M | $458.4M | ||
| Q4 24 | $862.9M | $502.4M | ||
| Q3 24 | $798.2M | $511.2M |
| Q2 26 | $120.0M | — | ||
| Q1 26 | $128.3M | — | ||
| Q4 25 | $128.3M | $33.7M | ||
| Q3 25 | $127.8M | $71.7M | ||
| Q2 25 | $131.6M | $39.3M | ||
| Q1 25 | $95.5M | $20.7M | ||
| Q4 24 | $123.2M | $30.5M | ||
| Q3 24 | $119.1M | $19.4M |
| Q2 26 | 99.9% | — | ||
| Q1 26 | 94.9% | — | ||
| Q4 25 | 43.1% | — | ||
| Q3 25 | 44.5% | — | ||
| Q2 25 | 45.3% | — | ||
| Q1 25 | 45.3% | — | ||
| Q4 24 | 42.5% | — | ||
| Q3 24 | 44.3% | — |
| Q2 26 | 43.3% | — | ||
| Q1 26 | 45.0% | — | ||
| Q4 25 | 20.4% | 9.9% | ||
| Q3 25 | 21.1% | 13.8% | ||
| Q2 25 | 21.7% | 12.8% | ||
| Q1 25 | 17.4% | 7.0% | ||
| Q4 24 | 19.2% | 7.8% | ||
| Q3 24 | 21.0% | 6.6% |
| Q2 26 | 30.1% | — | ||
| Q1 26 | 31.5% | — | ||
| Q4 25 | 14.3% | 6.8% | ||
| Q3 25 | 14.5% | 14.5% | ||
| Q2 25 | 15.2% | 8.4% | ||
| Q1 25 | 11.7% | 4.5% | ||
| Q4 24 | 14.3% | 6.1% | ||
| Q3 24 | 14.9% | 3.8% |
| Q2 26 | $1.61 | — | ||
| Q1 26 | $1.71 | — | ||
| Q4 25 | $1.71 | $0.40 | ||
| Q3 25 | $1.70 | $0.84 | ||
| Q2 25 | $1.74 | $0.46 | ||
| Q1 25 | $1.26 | $0.24 | ||
| Q4 24 | $1.61 | $0.37 | ||
| Q3 24 | $1.57 | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $586.2M | $375.2M |
| Total DebtLower is stronger | — | $570.5M |
| Stockholders' EquityBook value | $4.0B | $865.9M |
| Total Assets | $6.9B | $2.2B |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | $586.2M | — | ||
| Q1 26 | $580.0M | — | ||
| Q4 25 | $580.0M | $375.2M | ||
| Q3 25 | $593.8M | $340.1M | ||
| Q2 25 | $568.2M | $224.7M | ||
| Q1 25 | $594.1M | $99.0M | ||
| Q4 24 | $620.8M | $229.9M | ||
| Q3 24 | $633.2M | $103.8M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $1.8B | $570.5M | ||
| Q3 25 | $1.9B | $577.2M | ||
| Q2 25 | $1.9B | $583.9M | ||
| Q1 25 | $2.0B | $590.5M | ||
| Q4 24 | $2.0B | $597.1M | ||
| Q3 24 | $2.1B | — |
| Q2 26 | $4.0B | — | ||
| Q1 26 | $4.0B | — | ||
| Q4 25 | $4.0B | $865.9M | ||
| Q3 25 | $4.0B | $890.7M | ||
| Q2 25 | $4.0B | $833.8M | ||
| Q1 25 | $3.9B | $789.2M | ||
| Q4 24 | $3.8B | $764.9M | ||
| Q3 24 | $3.8B | $732.5M |
| Q2 26 | $6.9B | — | ||
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.9B | $2.2B | ||
| Q3 25 | $7.0B | $2.2B | ||
| Q2 25 | $6.9B | $2.1B | ||
| Q1 25 | $6.8B | $2.0B | ||
| Q4 24 | $6.7B | $2.2B | ||
| Q3 24 | $7.0B | $2.1B |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 0.45× | 0.66× | ||
| Q3 25 | 0.48× | 0.65× | ||
| Q2 25 | 0.46× | 0.70× | ||
| Q1 25 | 0.50× | 0.75× | ||
| Q4 24 | 0.52× | 0.78× | ||
| Q3 24 | 0.55× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $114.1M |
| Free Cash FlowOCF − Capex | $86.0M | — |
| FCF MarginFCF / Revenue | 21.6% | — |
| Capex IntensityCapex / Revenue | 4.4% | — |
| Cash ConversionOCF / Net Profit | — | 3.39× |
| TTM Free Cash FlowTrailing 4 quarters | $654.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $209.5M | $114.1M | ||
| Q3 25 | $203.5M | $137.3M | ||
| Q2 25 | $161.7M | $137.2M | ||
| Q1 25 | $105.7M | $-117.5M | ||
| Q4 24 | $172.6M | $133.0M | ||
| Q3 24 | $205.3M | $91.8M |
| Q2 26 | $86.0M | — | ||
| Q1 26 | $189.8M | — | ||
| Q4 25 | $189.8M | — | ||
| Q3 25 | $188.7M | — | ||
| Q2 25 | $146.9M | — | ||
| Q1 25 | $91.4M | — | ||
| Q4 24 | $157.1M | — | ||
| Q3 24 | $191.6M | — |
| Q2 26 | 21.6% | — | ||
| Q1 26 | 46.6% | — | ||
| Q4 25 | 21.1% | — | ||
| Q3 25 | 21.5% | — | ||
| Q2 25 | 17.0% | — | ||
| Q1 25 | 11.2% | — | ||
| Q4 24 | 18.2% | — | ||
| Q3 24 | 24.0% | — |
| Q2 26 | 4.4% | — | ||
| Q1 26 | 15.6% | — | ||
| Q4 25 | 2.2% | — | ||
| Q3 25 | 1.7% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 1.8% | — | ||
| Q3 24 | 1.7% | — |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 1.63× | 3.39× | ||
| Q3 25 | 1.59× | 1.91× | ||
| Q2 25 | 1.23× | 3.49× | ||
| Q1 25 | 1.11× | -5.66× | ||
| Q4 24 | 1.40× | 4.36× | ||
| Q3 24 | 1.72× | 4.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IEX
Segment breakdown not available.
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
